



No.F.2-6/2024 DD (RRR)
Government of Pakistan
Ministry of National Health Services, Regulation & Coordination
Drugs Regulatory Authority of Pakistan
(Division of Pharmaceutical Evaluation & Registration)

Islamabad, the 22nd October, 2025


NOTIFICATION

SUBJECT: PRODUCT SPECIFICATION OF MECOBALAMIN / METHYCOBALAMIN TABLET

I am directed to refer to the subject captioned above. PQCB Punjab sought advice on product specification of tablet containing Mecobalamin / Methylcobalamin. Registration Board in its 348th meeting held on 1st & 2nd July, 2025, deliberated on the subject matter and decided that the Mecobalamin / Methylcobalamin Tablet monograph is available as drug product in Japanese Pharmacopoeia. Hence, all the registration holders should follow JP monograph of Mecobalamin/ Methylcobalamin Tablet.

2. In the light of above-mentioned decision all manufacturers / MA holders having registration of the tablet containing Mecobalamin / Methylcobalamin are advised to apply for change of specifications in relevant section of PE&R Division within Six months of issuance of this notification.

3. Accordingly, above decision of Registration Board is hereby circulated for information and compliance for all relevant stakeholders.


(SANA KANWAL)
Deputy Director, PE&R

Distribution:

1. Chairman, Pakistan Pharmaceutical Manufacturer's Association, Islamabad.
2. Executive Director, Pharma Bureau, Karachi.
3. Executive Director, Pakistan Chemist and Druggist Association, Karachi.

Through E-office:

1. PS to CEO, DRAP, Islamabad
2. Director (MIS), DRAP for uploading on DRAPs website.
3. Additional Director / Office In-charge DRAP Karachi, Lahore, Islamabad, Peshawar, Quetta for circulation to pharmaceutical units located in their respective area of jurisdiction